Advertisement

HIV-Infektion – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung

  • Stefan EsserEmail author
Living reference work entry
Part of the Springer Reference Pflege – Therapie – Gesundheit book series (SRPTG)

Zusammenfassung

Durch die breite Einführung einer effektiven antiretroviralen Therapie sinken die Mortalität und Morbidität der HIV-Infektion, wodurch die Prävalenz infolge der verbesserten Lebenserwartung bei nur langsam abfallender Inzidenz steigt. Noch immer werden HIV-Infektionen häufig erst in fortgeschrittenen Stadien diagnostiziert. Neben Aufklärung und Abbau von Testbarrieren stehen zahlreiche Möglichkeiten zur Prävention einer HIV-Infektion zur Verfügung. Diese reichen vom Kondomgebrauch und Nadel-/Spritzentausch über die Einnahme einer Prä- oder Post-Expositionsprophylaxe bis hin zu Konzepten wie „Test and Treat“ und „Treatment as Prevention“ einschließlich Kampagnen wie „Undetectable equals untransmittable“ (U=U). Die effektivste Methode zur HIV-Prävention und Gesundheitsförderung bei HIV-Infizierten ist die frühzeitige Diagnose der HIV-Infektion und Einleitung der antiretroviralen Therapie.

Literatur

  1. Antiretroviral Therapy Cohort Collaboration (2010) Causes of death in HIV-1–infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50:1387–1396CrossRefGoogle Scholar
  2. Baeten JM, Donnell D et al (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367:399–410CrossRefGoogle Scholar
  3. Charlebois ED, Das M et al (2011). The effect of expanded anti-retroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 52 (8):1046–1049.  https://doi.org/10.1093/cid/cir085 (PMID: 21460322)
  4. Cohen MS, Chen YQ, HPTN 052 Study Team et al (2016) Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 375(9):830–839CrossRefGoogle Scholar
  5. Dirks H, Esser S et al (2012) Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med 13(9):533–540PubMedGoogle Scholar
  6. Dirks H, Esser S et al (2017) Dramatic changes over time of methamphetamine intake in a German, HIV-positive, sample of men who have sex with men (MSM). Pharmacopsychiatry 50(3):123–124CrossRefGoogle Scholar
  7. Egger M, May M et al (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360(9327):119–129CrossRefGoogle Scholar
  8. Esser S, Gelbrich G et al (2013) Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol 102(3):203–213CrossRefGoogle Scholar
  9. Esser S, Kreuter A et al (2015) German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. J Dtsch Dermatol Ges 13(12):1302–1319CrossRefGoogle Scholar
  10. Esser S, Krotzek J et al (2017) Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV-positive men who have sex with men (MSM) – approaches for medical prevention. J Dtsch Dermatol Ges 15(4):421–428PubMedGoogle Scholar
  11. Grant RM, Lama JR, iPrEx Study Team et al (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27):2587–2599CrossRefGoogle Scholar
  12. Gueler A, Moser A et al (2017) Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 31(3):427–436PubMedPubMedCentralGoogle Scholar
  13. Helleberg M, Afzal S et al (2013) Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 56(5):727–734CrossRefGoogle Scholar
  14. INSIGHT START Study Group, Lundgren JD et al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373(9):795–807CrossRefGoogle Scholar
  15. Katzenstein DA, Hammer SM et al (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 335(15):1091–1098CrossRefGoogle Scholar
  16. Lang S, Mary-Krause M, French Hospital Database on HIV-ANRS CO4 et al (2010) Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 24(8):1228–1230CrossRefGoogle Scholar
  17. McCormack S, Dunn DT et al (2016) Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387:53–60CrossRefGoogle Scholar
  18. Molina J-M, Capitant C et al (2015) On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 373:2237–2246CrossRefGoogle Scholar
  19. Molina J-M, Charreau I et al (2017) Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 4:e402–e410CrossRefGoogle Scholar
  20. Robert Koch-Institut (RKI): Epidemiologisches Bulletin Nr. 47; 23. November 2017Google Scholar
  21. Robert Koch-Institut (RKI): Epidemiologisches Bulletin Nr. 47; 22. November 2018Google Scholar
  22. Rodger AJ, Cambiano V, PARTNER Study Group et al (2016) Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316(2):171–181CrossRefGoogle Scholar
  23. Schouten J, Wit FW, AGEhIV Cohort Study Group et al (2014) Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 59(12):1787–1797CrossRefGoogle Scholar
  24. Shepherd L, Borges Á, EuroSIDA in EuroCOORD et al (2016) Infection-related and -unrelated malignancies, HIV and the aging population. HIV Med 17(8):590–600CrossRefGoogle Scholar
  25. Smith DK, Herbst JH et al (2015) Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. JAIDS 68(3):337±44Google Scholar
  26. Spinner CD, Boesecke C et al (2016) HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection 44(2):151–158CrossRefGoogle Scholar
  27. Strathdee SA, Abramovitz D et al (2013) Reductions in HIV/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PLoS One 8(6):e65812CrossRefGoogle Scholar
  28. Sullivan AK, Raben D et al (2013) Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One 8(1):e52845CrossRefGoogle Scholar
  29. Triant VA (2014) Epidemiology of coronary heart disease in patients with human immunodeficiency virus. Rev Cardiovasc Med 15(1):S1–S8. (Review)CrossRefGoogle Scholar
  30. Ward DJ, Rowe B et al (2005) Reducing the risk of sexually transmitted infections in genitourinary medicine clinic patients: a systematic review and meta-analysis of behavioural interventions. Sex Transm Infect 81(5):386–393. (Review)CrossRefGoogle Scholar
  31. World Health Organization (WHO) (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Dermatologie und Venerologie, HPSTD Ambulanz (HIV/AIDS, Proktologie, Sexuell übertragbare ErkrankungenUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations